RCEL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AVITA Medical Inc (RCEL) is not a strong buy at this moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While there are some positive catalysts such as hedge fund buying and analyst optimism, the technical indicators are bearish, financial performance shows declining revenue and EPS, and there are no strong proprietary trading signals to support an immediate buy decision. A hold is recommended until more favorable conditions emerge.
The technical indicators for RCEL are bearish. The MACD histogram is below 0 and negatively contracting, the RSI is neutral at 32.3, and moving averages are in a bearish alignment (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 3.854, with key support at 3.594 and resistance at 4.114.
Hedge funds are significantly increasing their positions in RCEL, with a 534.61% increase in buying over the last quarter. Analysts at Northland have reiterated an Outperform rating with a $10 price target, citing easing reimbursement uncertainty and potential for double-digit revenue growth.
The company's financial performance in Q4 2025 shows declining revenue (-4.30% YoY), a drop in EPS (-13.64% YoY), and a decrease in gross margin (-6.97% YoY). Additionally, there are no recent news catalysts or congress trading data to support a buy decision. Technical indicators remain bearish, and the stock's short-term trend suggests limited upside potential.
In Q4 2025, revenue dropped to $17.615 million (-4.30% YoY), net income improved slightly to -$11.621 million (+0.28% YoY), EPS decreased to -0.38 (-13.64% YoY), and gross margin declined to 81.9% (-6.97% YoY). These metrics indicate challenges in growth and profitability.
Analysts at Northland have an Outperform rating and a $10 price target, citing easing reimbursement uncertainty and potential for a return to 20%+ topline growth. However, Lake Street maintains a Hold rating with a $3.50 price target, citing a need for business stabilization and incremental confidence in the outlook.
